None of the 29 investors followed here reported a position in ATRA in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a ATRA trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -71.3 | 4.2 | -12.7 | 0.8 | 120.3 | 9.2 | -27.0 | 6.2 | -4.5 | 9.5 | −48.6% | ||
| 2025 | -33.3 | -22.2 | -14.0 | 34.5 | -2.4 | -1.0 | 49.2 | 4.6 | 18.9 | 3.6 | 1.7 | 19.8 | +35.9% |
| 2024 | 21.6 | 24.7 | -10.8 | -0.6 | -18.7 | -39.4 | 15.6 | -22.7 | 7.0 | 9.6 | 36.6 | 9.3 | +3.8% |
| 2023 | 54.6 | -20.1 | -28.4 | -6.6 | -43.5 | 5.2 | 37.3 | -33.9 | 1.4 | -12.8 | -48.8 | -22.3 | −84.4% |
| 2022 | -2.5 | -16.3 | -27.7 | -31.5 | -18.2 | 49.8 | -61.1 | 32.3 | -5.7 | 23.3 | -2.8 | -27.6 | −79.2% |
| 2021 | -6.0 | -9.1 | -14.4 | -2.1 | -3.6 | 14.7 | -18.0 | 17.5 | 19.5 | -13.5 | 15.6 | -11.9 | −19.7% |
| 2020 | -19.7 | -8.2 | -30.0 | -2.6 | 38.7 | 26.7 | -15.0 | 8.8 | -3.9 | -0.4 | 79.6 | -15.4 | +19.2% |
| 2019 | 9.4 | -5.8 | 11.0 | -15.5 | -33.9 | -9.5 | -29.0 | -5.4 | 4.6 | -22.7 | 30.1 | 15.9 | −52.6% |
| 2018 | 108.8 | 1.9 | 1.2 | 3.5 | 23.4 | -26.2 | 2.2 | 9.1 | 1.0 | -17.4 | 16.9 | -13.0 | +91.9% |
| 2017 | -5.3 | 14.9 | 33.0 | -16.8 | -22.5 | 5.7 | 8.9 | 3.3 | 5.1 | -14.2 | 1.8 | 25.3 | +27.5% |
| 2016 | -31.5 | -9.2 | 15.8 | -5.4 | 0.6 | 24.3 | 6.6 | -18.6 | 9.5 | -40.2 | 55.1 | -28.5 | −46.2% |
| 2015 | -8.9 | -19.7 | 112.5 | -0.3 | 2.2 | 24.6 | 6.4 | -27.8 | -22.4 | -18.0 | 52.5 | -32.8 | −1.3% |
| 2014 | 40.8 | -0.9 | +39.5% |
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 3, 2026 | Cherry Brian NDirector | Purchase at price 9.60 per share. | 104.2K | $999.99K |
| Aug 16, 2026 | Nguyen Anhco TChief Executive Officer | Sale at price 8.08 per share. | 5.1K | $40.88K |
| Jul 21, 2026 | Redmile Group, L.L.C.Unknown | — | 195.2K | — |
| Jun 10, 2026 | Cherry Brian NDirector | Stock Award(Grant) at price 0.00 per share. | 24K | — |
| Jun 8, 2026 | Fust Matthew K.Director | Stock Award(Grant) at price 0.00 per share. | 12K | — |
| Jun 8, 2026 | Heiden William KDirector | Stock Award(Grant) at price 0.00 per share. | 12K | — |
| Jun 8, 2026 | Ciongoli Gregory AustinDirector and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.00 per share. | 12K | — |
| May 17, 2026 | Nguyen Anhco TChief Executive Officer | Sale at price 9.13 per share. | 5.2K | $47.84K |
| May 17, 2026 | Grant-Huerta YaninaOfficer | Sale at price 9.13 per share. | 2.4K | $22.04K |
| May 6, 2026 | Ecor1 Capital, L.L.C.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 9.35 per share. | 507.4K | $4.74M |
| May 6, 2026 | Panacea Innovation LtdBeneficial Owner of more than 10% of a Class of Security | Sale at price 10.10 per share. | 313.4K | $3.17M |
| Mar 16, 2026 | Panacea Innovation LtdBeneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security at price 0.00 per share. | 259.2K | $26 |
| Mar 8, 2026 | Grant-Huerta YaninaOfficer | Stock Award(Grant) at price 0.00 per share. | 20.3K | — |
| Mar 1, 2026 | Nguyen Anhco TChief Executive Officer | Sale at price 5.08 - 5.09 per share. | 3K | $15.24K |
| Mar 1, 2026 | Grant-Huerta YaninaOfficer | Sale at price 5.08 per share. | 2.1K | $10.69K |
| Jan 11, 2026 | Panacea Innovation LtdBeneficial Owner of more than 10% of a Class of Security | Sale at price 6.07 per share. | 80.6K | $489.02K |
| Nov 27, 2025 | Panacea VentureBeneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security at price 0.00 per share. | 48.7K | $5 |
| Nov 16, 2025 | Nguyen Anhco TChief Executive Officer | Sale at price 13.19 per share. | 2.9K | $38.44K |
| Nov 16, 2025 | Grant-Huerta YaninaOfficer | Sale at price 13.19 per share. | 1.8K | $23.79K |
| Aug 17, 2025 | Nguyen Anhco TChief Executive Officer | Sale at price 11.61 - 11.62 per share. | 3K | $34.36K |
Buy / hold / sell counts
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.